The company also reaffirmed fiscal fourth quarter growth expectations including double-digit growth in the US for its TB testing products.
The firm has added two new targets to make the Sofia 2 POC Lyme+ Fluorescent Immunoassay more relevant to Lyme disease pathogens in Europe.
ChromaCode this week launched its first product, a research-use-only test for nine tick-borne pathogens designed for research use on any thermal cycler.
The researchers are using mass spectrometry to look in patient blood samples for peptides shed by Borrelia burgdorferi, the bacteria that causes Lyme disease.
A tick-borne disease working group recommends the federal government explore using new technologies and repurposing existing ones to improve diagnosis.
Earlier this week, the company closed the sale of its US laboratory business to Quest DIagnostics for $170 million in cash.
A diverse group of researchers and diagnostic industry participants has collaborated to produce two papers that describe and critique Lyme disease testing technologies.
The acquisition is expected to close in the fourth quarter and to increase US access to Oxford Immunotec Global's T-Spot.TB tuberculosis test.
The firm aims to bring to market a point-of-care technology that would significantly reduce the expense associated with highly sensitive diabetes testing.
The fluorescent immunoassay was cleared to run on the next-generation Sofia 2 platform and runs using a finger-stick whole-blood specimen.